Company: DRTSW
Filing Date: 2025-06-23
Form Type: F-3
Source: 0001213900-25-056744
Chunk: 6

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-06-23
Form: F-3
Chunk 6
---
 business;                                                                                           |

| ● | If we do not obtain and maintain                                                                                                     
 international regulatory registrations, marketing authorizations or certifications for any product candidates we develop, we will be 
 unable to market and sell such product candidates outside of the United States;                                                      |

| ● | If in the future our Alpha                                                                                                             
 DaRT technology is approved or certified for commercial sale, but we are unable to obtain adequate reimbursement or insurance coverage 
 from third-party payors, we may not be able to generate significant revenue;                                                           |

| ● | We may be unable to obtain                                                                                        
 a sufficient or sufficiently pure supply of radioisotopes to support clinical development or at commercial scale; |

| ● | If we are unable to obtain                                                                                                                    
 and maintain patent or other intellectual property protection for our Alpha DaRT technology and for any other products or product candidates  
 that we develop, or if the scope of the patent or other intellectual property protection obtained is not sufficiently broad, our competitors  
 could develop and commercialize products and technology similar or identical to ours, and our ability to commercialize any product candidates 
 we may develop, and our technology may be adversely affected;                                                                                 |

| ● | We are incurring increased                                                                                                     
 costs as a result of operating as a public company, and our management will devote substantial time to compliance initiatives; |

| ● | Conditions in Israel could materially and adversely affect 
 our business; and                                          |

| ● | The other matters described in the section titled “Risk 
 Factors” beginning on page 6.                           |

We
caution you against placing undue reliance on forward-looking statements, which reflect current beliefs and are based on information currently
available as of the date a forward-looking statement is made. Forward-looking statements set forth herein speak only as of the date of
this prospectus. We undertake no obligation to revise forward-looking statements to reflect future events, changes in circumstances, or
changes in beliefs. In the event that any forward-looking statement is updated, no inference should be made that we will make additional
updates with respect to that statement, related matters, or any other forward-looking statements. Any corrections or revisions and other
important assumptions and factors that could cause actual results to differ materially from forward-looking statements, including discussions
of significant risk factors, may appear in our public filings with the SEC, which are or will be (as appropriate) accessible at www.sec.gov,
and which you are advised to consult. For additional information, please see the section titled “Where You Can Find More Information